Inpharma

Antibacterials remain controversial in acute pancreatitis
pp. 2-2(1)

The future of noncommercial research in EU member states is threatened by a new EU directive
pp. 3-3(1)

FLT-3 inhibitors: promising targeted therapy for paediatric cancer
pp. 3-3(1)

Does malaria prophylaxis interact with vaccinations in infants?
pp. 3-3(1)

Chemotherapy-induced nausea and vomiting costly in Germany
pp. 4-4(1)

GPIIb-IIIa antagonists for women with ACS: good or bad?
pp. 4-4(1)

Artesunate/amodiaquine will replace chloroquine as the first-line treatment for malaria in Ghana
pp. 4-4(1)

Antiulcer coprescribing threatens COX-2 inhibitor cost savings
pp. 5-5(1)

Oral phenytoin least costly option for ED treatment of seizures
pp. 5-5(1)

Spinal cord stimulation (SCS) offers economic benefits for the treatment of chronic pain by paying for itself in less than 2.5 years
pp. 5-5(1)

Azimilide reduced the incidence of atrial fibrillation (AF) but had no effect on mortality in patients with left ventricular dysfunction after recent myocardial infarction
pp. 6-6(1)

Ranolazine promising in chronic angina pectoris
pp. 6-6(1)

Pregabalin successfully treats social phobia
pp. 6-6(1)

Intranasal ciclesonide nothing to sneeze at in allergic rhinitis
pp. 7-7(1)

Salcaprozate sodium enables GI absorption of oral insulin
pp. 8-8(1)

Sardomozide active in poor prognosis NHL
pp. 8-8(1)

Edodekin- improves HPV-specific immune response in cervical cancer
pp. 8-8(1)

Virosome-adjuvanted flu vaccine safe and highly immunogenic
pp. 9-9(1)

Low-dose estradiol/drospirenone effectively prevents postmenopausal osteoporosis
pp. 9-9(1)

Tipranavir in a new SEDDS formulation, combined with ritonavir, has potent antiviral efficacy in treatment-naive patients with HIV-1 infection
pp. 9-9(1)

Rate-control drugs AFFIRMed, but survival benefit questioned
pp. 10-10(1)

Tegafur/uracil: beneficial adjuvant for stage I lung adenocarcinoma
pp. 10-10(1)

Budesonide/formoterol single inhaler therapy superior in asthma
pp. 11-12(2)

Poorer survival with high-dose epinephrine in cardiac arrest
pp. 12-12(1)

The brain lesions in a patient with neurosarcoidosis demonstrated dramatic responsiveness to cladribine
pp. 12-12(1)

Mycophenolate mofetil monitoring of substantial clinical benefit
pp. 13-13(1)

Antidepressants are effective in the treatment of depression in patients with concurrent alcohol or drug dependence
pp. 13-13(1)

Somatropin effective in HIV-associated wasting
pp. 13-13(1)

Lornoxicam more effective than rofecoxib for active osteoarthritis
pp. 14-14(1)

Sotalol or amiodarone + metoprolol prevent AF after cardiac surgery
pp. 14-14(1)

Low-dose risperidone is effective and well tolerated in patients with first-episode schizophrenia
pp. 14-14(1)

Long-term tibolone improves bone mineral density (BMD) in postmenopausal osteoporosis
pp. 14-14(1)

Haloperidol effectively prevents PONV
pp. 15-15(1)

Irbesartan renoprotective in type 2 diabetes mellitus
pp. 15-15(1)

Bivalirudin may be beneficial during surgical revascularisation
pp. 15-15(1)

Long-term mood stabilisers improve schizoaffective symptoms
pp. 15-15(1)

Ezetimibe significantly and progressively improves sitosterol and campesterol levels in patients with sitosterolaemia
pp. 16-16(1)

An association between biological response to infliximab and FCGR3A-158 polymorphism exists in patients with Crohn's disease
pp. 16-16(1)

HAART reduces the risk of HIV-associated nephropathy
pp. 16-16(1)

The atypical antipsychotic, quetiapine, appears to be effective and safe in the treatment of patients with delirium
pp. 16-16(1)

Testosterone treatment can improve exercise capacity and symptoms in men with chronic heart failure (HF)
pp. 16-16(1)

Long-term lopinavir/ritonavir effective in HIV infection
pp. 18-18(1)

Imatinib pharmacokinetics in CML and ALL patients
pp. 18-18(1)

Macrolide therapy has no effect on cardiac outcomes in patients with acute coronary syndromes or coronary artery disease
pp. 18-18(1)

Metoprolol reduces coronary collateral flow during PTCA
pp. 19-19(1)

Suxamethonium chloride had an antidysrhythmic effect in a patient with supraventricular tachycardia
pp. 19-19(1)

Rifampicin significantly alters the pharmacokinetics of rosiglitazone in healthy subjects
pp. 19-19(1)

Statins: no effect on coronary collateral flow in CAD
pp. 19-19(1)

More studies needed on cognitive effects of AEDs in children
pp. 20-20(1)

Are SSRIs really `safe' and efficacious in childhood depression?
pp. 20-20(1)

Lopinavir/ritonavir concentrations not linked to lipid abnormalities?
pp. 20-20(1)

Use enoxaparin and UFH with caution in renal insufficiency
pp. 21-21(1)

A 3-year study investigating the feasibility of active surveillance methods for generating data on serious and life-threatening ADRs
pp. 21-21(1)

US market approvals
pp. 21-21(1)

Ciclesonide [Alvesco; Altana Pharma] has been approved for marketing in the UK
pp. 21-21(1)

A generic version of tadalafil has been launched in India
pp. 22-22(1)

Recent US product launches
pp. 22-22(1)

US regulatory news
pp. 22-22(1)

Octreotide [Sandostatin LAR; Novartis] has been approved in Japan for the treatment of acromegaly and symptoms of gastrointestinal hormone-secreting tumours.
pp. 22-22(1)

Schering-Plough Corporation has received a positive opinion recommending approval of an expanded indication for infliximab [Remicade] in the EU.
pp. 22-22(1)

QLT Inc. has announced that verteporfin [Visudyne] is now reimbursed in Japan.
pp. 22-22(1)

Product Introductions
pp. 23-23(1)